Dejan Juric reports on the results presented at ASCO 2018 from studies that tested addition of selective PIK3CA inhibitor in selected populations of patients, but the treatment caused considerable side effects.
Perspectives from ASCO 2018: Highlights in drugging PIK3CA-mutated tumours: The SANDPIPER and MATCH trials